Format

Send to

Choose Destination
Dermatology. 2007;214(4):325-7.

Hidradenitis suppurativa and zinc: a new therapeutic approach. A pilot study.

Author information

1
Department of Dermatology, INSERM U601, CHU Hôtel-Dieu, Nantes, France.

Abstract

BACKGROUND:

Hidradenitis suppurativa (Verneuil's disease) is a chronic suppurative dermatosis involving apocrine glands with a severe impact on the quality of life, which is enhanced by the fact that the drugs usually prescribed are poorly effective.

OBJECTIVE:

We discuss a new therapeutic approach based on zinc salts.

METHODS:

We performed a pilot study on 22 patients, mainly from grade I or II in Hurley's classification. All included patients had previously been prescribed a treatment (antibiotic, isotretinoin, surgery or anti-androgens), which was inefficient. They were then treated with 90 mg of zinc gluconate per day (15 mg zinc per Rubozinc capsule).

RESULTS:

We observed a clinical response in all patients, with 8 complete remissions (CR) and 14 partial remissions (PR). When CR was obtained, the treatment was progressively decreased (average of 3.5 capsules/day); 4/22 patients experienced side-effects, mainly gastro-intestinal.

CONCLUSION:

Zinc salts could provide a new therapeutic alternative for the treatment of hidradenitis suppurativa.

PMID:
17460404
DOI:
10.1159/000100883
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for S. Karger AG, Basel, Switzerland
Loading ...
Support Center